Bone Medical Ltd (BNE), an international biopharmaceutical company focused on the development of important new medicines for the treatment of musculoskeletal diseases like osteoporosis and arthritis, is pleased to announce that its Axcess III oral peptide formulation technology patent has been granted in Japan.
Dr. Roger New, Chairman, Chief Scientific Officer, and inventor of the Axcess technology, commented, “Axcess III is the specific version of our oral formulation technology that we use in our proprietary oral peptide product Capsitonin, oral calcitonin for osteoporosis and arthritis pain. Long-term treatment of these chronic conditions is an area of serious unmet clinical need due to safety, tolerability, and drug interaction problems. Capsitonin has significant potential safety and compliance advantages over existing therapies for these diseases.” “We recently announced the issue of our Axcess II patent in Japan. The grant of Axcess III in Japan extends our proprietary position in the Japanese market, one of the largest and most significant pharmaceutical markets in the developed world,” added Dr. New. “This additional progress caps the success we have had in the first half of 2012 establishing an effective global patent foundation for all our products.”
Bone Medical Limited is an international biopharmaceutical company focused on developing significant new products for the growing market in the treatment of bone disease, especially osteoporosis and arthritis. The Company has an exclusive world-wide license to the underlying technologies used in all these products in its target disease fields from Proxima Concepts Ltd.